One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Eyenovia logo
Eyenovia EYEN
report update icon

Quarterly report 2026-Q1
added 05-15-2026

Eyenovia Income Statement 2025-2011 | EYEN

Brief overview of revenue and earnings at Eyenovia

The conclusions below are based on five years of reported results. Revenue at Eyenovia moved from 2 million dollars in 2020 to 813 thousand dollars in 2025. The total change was −59.3%, with a CAGR of approximately −16.5%. The negative rate indicates weakening core operations.

Gross profit was 1.2 million dollars at the start and 510 thousand dollars at the end of the period (−57.5%). Direct costs broadly followed the top-line trend. The gross margin was 60% at the start and 62.7% at the end. The expansion indicates stronger pricing power or better control of direct costs.

EBITDA was −$19.7 million at the beginning and −$46.7 million at the end of the period (−137.4%). The operating result developed less favorably than sales. EBITDA margin was −984.2% at the start and −5743.5% at the end. Operating return per unit of revenue declined.

Comparing the endpoints shows a move from −$19.8 million to −$45.3 million. The period ended with a larger loss than it began with.

What the figures show

The indicators point to a weaker financial profile. Key strengths include improving gross profitability. The main areas of concern are a low EBITDA margin, weaker operating efficiency and a weaker final result. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Eyenovia

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 800 K 785 K 103 M 105 M 150 M 66.6 M 31.2 M 95.4 M - - - - - -

Shares

5 M 833 K 513 K 33.6 M 26.3 M 24.9 M 14.3 M 9.48 M 9.94 M - - - - - -

Historical Prices

- 0.96 1.53 3.05 4 6.06 4.48 2.85 - - - - - - -

Net Income

-45.3 M -49.8 M -27.3 M -28 M -12.8 M -19.8 M -21.2 M -17.3 M -5.13 M -3.53 M -4.27 M - - - -

Revenue

813 K 57.3 K 3.79 K - 14 M 2 M - - - - - - - - -

Cost of Revenue

303 K 3.93 M 16 K - 1.6 M 800 K - - - - - - - - -

Gross Profit

510 K -3.87 M -12.2 K - 12.4 M 1.2 M - - - - - - - - -

Operating Income

-46.7 M -48.7 M -25.4 M -26.9 M -13 M -19.8 M -21.3 M -17.3 M -5.13 M -3.53 M - - - - -

Interest Expense

390 K -90.6 K 2.37 M 1.38 M 388 K 17 K - - - - - - - - -

EBITDA

-46.7 M -47.6 M -24.6 M -26.6 M -12.8 M -19.7 M -21.3 M -17.2 M -5.11 M -3.52 M -4.26 M - - - -

Operating Expenses

47.2 M 44.9 M 25.4 M 26.9 M 25.4 M 21 M 21.3 M 17.3 M - - - - - - -

General and Administrative Expenses

17.2 M 14.3 M 12.4 M 13.5 M 10.6 M 7.73 M 7.21 M 6.14 M 1.32 M 569 K 1.49 M - - - -

All numbers in USD currency

Quarterly Income Statement Eyenovia

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

10.6 M 6.03 M 3.52 M 2.19 M 1.51 M 69.6 M 664 K 583 K 45.6 M 40.1 M 38.1 M 37.4 M 36.7 M 34.6 M 33.6 M 30 M 28.4 M 26.1 M 25.9 M 25.3 M 25 M 22.2 M 19.8 M 17.3 M 17.1 M 16.3 M 12 M 11.9 M 11.5 M 10 M 10 M 7.56 M 2.57 M 8.51 M 2.27 M 2.27 M 2.27 M - - - - - - - - - - - - - - - - - - - - - - -

Net Income

8.84 M 6.63 M -8.69 M -3.48 M - -7.89 M -11.1 M -10.9 M - -7.34 M -6.22 M -5.74 M - -7.31 M -7.24 M -7.34 M - -5.57 M -4.84 M -5.35 M - -5.1 M -5.02 M -5.45 M - -4.65 M -5.33 M -5.93 M - -4.32 M -3.32 M -3.43 M - -885 K -977 K -1.11 M - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

244 K 303 K - 14.7 K - 1.62 K 22.6 K 4.99 K - 1.2 K - - - - - - - - 2 M 2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

48 48 - 48 - 133 K 490 K 203 K - 13.4 K - - - - - - - - 800 K 800 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

244 K 303 K - 14.7 K - -131 K -468 K -198 K - -12.2 K - - - - - - - - 1.2 M 1.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

8.73 M 4.43 M -8.35 M -3.03 M - -7.33 M -11.7 M -10.3 M - -6.52 M -5.96 M -5.46 M - -7.23 M -7.12 M -7.19 M - -5.93 M -4.78 M -5.37 M - -5.09 M -5.02 M -5.47 M - -4.69 M -5.38 M -5.95 M - -4.32 M -3.32 M -3.43 M - -885 K -977 K -1.11 M - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

90.1 K 132 K 169 K 3.69 K - 1.18 K 2.98 K -97.6 K - -348 K 119 K 454 K - 177 K 153 K 145 K - 119 K 78 K 5.15 K - 4.94 K 6.35 K 3.68 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

8.73 M 5.26 M - - - - - -10 M - - - -5.4 M - -7 M -6.98 M -7.11 M - -5.78 M -4.71 M -5.33 M - -5.02 M -4.97 M -5.44 M - -4.68 M -5.37 M -5.95 M - -4.3 M -3.31 M -3.43 M - -873 K -964 K -1.1 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

-8.49 M -4.13 M 8.35 M 3.05 M - 7.2 M 11.2 M 10.1 M - 6.51 M 5.96 M 5.46 M - 7.23 M 7.12 M 7.19 M - 5.93 M 5.98 M 6.57 M - 5.09 M 5.02 M 5.47 M - 4.69 M 5.38 M 5.95 M - 4.32 M 3.32 M 3.43 M - 885 K 977 K 1.11 M - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

4.49 M 2.59 M 7.68 M 2.37 M - 3.73 M 3.76 M 3.64 M - 2.93 M 3.15 M 2.94 M - 3.35 M 3.53 M 3.47 M - 2.37 M 2.3 M 2.24 M - 1.73 M 2.1 M 1.84 M - 1.49 M 1.81 M 1.94 M - 1.83 M 909 K 1.34 M - 315 K 225 K 196 K - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Eyenovia (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
FibroGen FibroGen
FGEN
- - $ 889 M usaUSA
Homology Medicines Homology Medicines
FIXX
- 0.77 % $ 53.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
- - $ 4.47 B usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
- - $ 528 M usaUSA
Galecto Galecto
GLTO
- - $ 762 M danmarkDanmark
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Graybug Vision Graybug Vision
GRAY
- -11.23 % $ 9.65 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
Hoth Therapeutics Hoth Therapeutics
HOTH
- - $ 18.8 M usaUSA
IMARA IMARA
IMRA
- 15.96 % $ 663 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
- - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
- -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
- - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
- - $ 63.4 M usaUSA
Magenta Therapeutics Magenta Therapeutics
MGTA
- -7.74 % $ 41.6 M usaUSA
NovaBay Pharmaceuticals NovaBay Pharmaceuticals
NBY
- - $ 11.3 M usaUSA
NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals
NRBO
- 0.43 % $ 12 M usaUSA
OncoCyte Corporation OncoCyte Corporation
OCX
- 17.22 % $ 355 K usaUSA
Onconova Therapeutics Onconova Therapeutics
ONTX
- -0.47 % $ 21 M usaUSA
Opthea Limited Opthea Limited
OPT
- - $ 1.2 B australiaAustralia
BiomX BiomX
PHGE
$ 1.85 14.2 % $ 3.02 M israelIsrael
Pieris Pharmaceuticals Pieris Pharmaceuticals
PIRS
- -15.58 % $ 1.22 B germanyGermany
Plus Therapeutics Plus Therapeutics
PSTV
- - $ 301 M usaUSA
Pluristem Therapeutics Pluristem Therapeutics
PSTI
- -1.9 % $ 33.3 M israelIsrael
Qualigen Therapeutics Qualigen Therapeutics
QLGN
- 5.59 % $ 1.16 M usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Cassava Sciences Cassava Sciences
SAVA
- - $ 110 M usaUSA
Selecta Biosciences Selecta Biosciences
SELB
- -8.69 % $ 126 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
- - $ 50.4 M usaUSA
Salarius Pharmaceuticals Salarius Pharmaceuticals
SLRX
- - $ 2.64 M usaUSA
Sensei Biotherapeutics Sensei Biotherapeutics
SNSE
- - $ 17.5 M usaUSA
Sonnet BioTherapeutics Holdings Sonnet BioTherapeutics Holdings
SONN
- - $ 826 K usaUSA
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Synlogic Synlogic
SYBX
- - $ 7.07 M usaUSA
Virios Therapeutics, LLC Virios Therapeutics, LLC
VIRI
- 2710.01 % $ 72.9 M usaUSA
Vallon Pharmaceuticals Vallon Pharmaceuticals
VLON
- -6.47 % $ 5.76 M usaUSA
Vaxart Vaxart
VXRT
- -25.06 % $ 46.3 M usaUSA
XOMA Corporation XOMA Corporation
XOMA
- - $ 485 M usaUSA
Repare Therapeutics Repare Therapeutics
RPTX
- - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
- 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia